Taylor Robichaux, PharmD, BCPS

Last night, the AC Forum staff team, Board President Allison Burnett, and our amazing PGY2 Thrombosis and Hemostasis (THM) residents and program directors came together for a memorable dinner at ASHP. We are so grateful for the dedication and passion of this incredible group! 👉 Attend today’s Residency Showcase to meet the current leaders and ask questions about this emerging specialty, or stop by booth 313, and we will help connect you with the right site. Learn more about the PGY2 THM program: bit.ly/4fysOtJ Find PGY2 opportunities at ASHP Midyear: bit.ly/4fvQyiD #ACForum #Thrombosis #Anticoagulation #PGY2 #ASHP24 @ashpofficial

We are excited to be at the ASHP 2024 Midyear meeting. If you are attending, stop by the AC Forum table #313 and say hello to our team! Learn about our Thrombosis and Hemostasis Management (THM) residency program (Residency Showcase at 1pm today & twice tomorrow) and grab a pair of our famous compression socks. Explore the ASHP Resident Matching Program: bit.ly/4fvQyiD Find PGY2 opportunities at ASHP Midyear: bit.ly/4fysOtJ Learn about the THM programs funded by our TRAIN Grant (all current sites are actively recruiting!): bit.ly/4fysOtJ We look forward to meeting you! #ACForum #Thrombosis #Anticoagulation #PGY2 @ashpofficial @acforum_darren #ASHP24

We’re excited to share our latest Rapid Recap (November 2024), featuring a comprehensive write-up of the most impactful anticoagulation articles from last month. Highlights include: 🔹 Anticoagulant therapy in pregnant women with mechanical and bioprosthetic heart valves 🔹 Secondary Prophylaxis of VTE with Low Dose Apixaban or Rivaroxaban in Major-thrombophilia Carriers 🔹 Development and Validation of Prognostic Models for Bleeding and Ischemia in Elderly Patients With Comorbid ACS and AF 🔹 Overview and Future Direction of Embolic Stroke of Undetermined Source from the Insights of CHALLENGE ESUS/CS Registry 🔹 Clinical Features, Management, and Recurrence of Acute Ischemic Stroke Occurring in Patients on Oral Anticoagulant Treatment for Nonvalvular Atrial Fibrillation: A Real-world Retrospective Study Authored by Taylor Robichaux, PharmD, this issue is packed with valuable insights for healthcare professionals. Access the full Rapid Download today! > bit.ly/3Vn2mvx #anticoagulation #medicalresearch #pharmacists #literatureupdate #healthcareprofessionals

📣 📣 JHH is recruiting for 1️⃣ PGY2 THM position🩸 for 2025-2026. Please reach out to schedule time to discuss at ASHP MCM PPS or Showcase, or elsewhere as needed. More info here: hopkinsmedicine.org/pharmacy/resid…

1/ FDA hearing on #andexanet alfa is tomorrow (21 Nov 2024). The documents contain some more data on thrombotic events that weren't published in ANNEXA-I. To be honest, reading through, I have found this data pretty shocking. A 🧵

Huge congratulations to @acforum_darren, our Director of Strategic Initiatives, for not only reaching his fundraising goal but also crossing the finish line at the NYC Marathon this November! Darren ran in memory of Leschel, who tragically passed away from a pulmonary embolism caused by DVT. Thanks to your generosity and support, Darren’s efforts to raise awareness about PE and DVT have made a real difference. As Darren says, “I’m incredibly grateful for the support of my friends, family, and colleagues. Your generosity has helped me reach my fundraising goal and make a real difference. Thank you!” Join us in celebrating Darren’s achievement and his commitment to saving lives through awareness and action. #NYCMarathon #DVTawareness #PEawareness #ACForum #StopTheClot

We’re excited to share the latest October 2024 Rapid Recap, featuring a comprehensive write-up of the most impactful anticoagulation articles. This month's highlights include: 🔹 Utility of the Modified Ottawa Score to Identify Preferable Candidates for Extended Anticoagulation in Cancer-Associated Isolated Distal DVT - Insights from the ONCO DVT Study 🔹 Pharmacist Use of a Population Management Dashboard for Safe Anticoagulant Prescribing - Nationwide Implementation Effort 🔹 Anticoagulant Therapy in Patients Undergoing Acute Pulmonary Embolism Interventions 🔹 Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage 🔹 The Use of DOACs in Secondary Prevention of VTE in Patients with Severe Thrombophilia Curated by Brandon Cave, PharmD, this issue is packed with valuable insights for healthcare professionals. Don’t miss out on these key updates. Access the full Rapid Recap here: bit.ly/4hFd1eC #anticoagulation #medicalresearch #pharmacists #literatureupdate #healthcareprofessionals

How does @MarcCarrier1 approach the choice between #DOAC and #LMWH for patients with #cancer assoc #VTE? Here are his key decision factors

Reducing AC dose after a bleeding event may increase the risk of thrombotic events and does not significantly decrease incidences of bleeding ‼️🩸 #ACstewardship

🔊 Resource Alert: July Rapid Recap! Our free Rapid Recaps distill the top articles from the past month. Thank you authors Cooper Hamilton & Kelly Rudd, & editorial team Candace Bryant, Greg Hadlock, Tara Lech, Carlee O'Connor & Bishoy Ragheb! Download: bit.ly/3ybk64u

#SickleCell is the most common monogenetic disease in the world. No better way to celebrate World Sickle Cell Day than to light up the iconic @HopkinsMedicine Dome red! Shout out to our @HopkinsHeme #HemeDreamTeam who are tireless advocates for our #sicklecell patients!

🚨🚨NEW #RPTH Illustrated Review🎨🖼️: DOACs for treatment of venous thrombosis: illustrated review of appropriate use @CandrikaDini @AntoineBejjani_ @aliassi19 @nicoleporio @AzitaTalasaz @GregoryPiazza4 @MaryCushmanMD @bbikdeli @sholzberg READ: rpthjournal.org/article/S2475-…

The factor Xa inhibitor reversal agent andexanet reduced expansion of intracerebral hemorrhages caused by factor Xa inhibitors but resulted in more thrombotic events than usual care. Read the full ANNEXA-I trial results: nej.md/3wAoERb

🛑Another negative trial for TXA in 🧠world 🩸 1. No utility in aSAH (removed from 2023 guidelines) 2. Now NO effect in ICH expansion compared to placebo when given within 2 hours of onset⁦ thelancet.com/journals/laneu…

It's #WorldHemophiliaDay - to show our support, we're offering a 20% discount on ASHP's Non-Malignant Hematology Certificate designed for pharmacists to enhance their knowledge and skills in non-malignant hematology drug therapy and pharmacy practice. Use code NMH20 to save: elearning.ashp.org/products/9873/…

Excited to present the results of our UFH calculator at #THSNA! It has been a great conference with the other #THM residents! #ACForum #ACstewardship

Excited for Day 2 of #THSNA2024! Say hello to our #PGY2 Residents at: ✔️ 12:45 Booth #502 @alyssa_g_pharmD (@BrighamWomens) ✔️ 4:30 Booth #618 @t_robipharmd (@JohnsHopkins) ✔️ 4:30 Booth #619 @poppywang28 (@HenryFordHealth) #ACStewardship #AnticoagStewardship

A retrospective review by Ochsner Health pharmacists found a high rate of inappropriate use of triple-antithrombotic therapy, especially treatment that exceeded 30 days and may have placed patients at increased risk for bleeding. doi.org/10.1093/ajhp/z…

In this #RPTH Original Article, authors report observational data on #DOAC prescribing from 2017-2019 the most common errors include💊🔍: 🚨Dose related errors 🚨Improper drug selection 🚨DDIs 🚨Avoidance of ADRs Read here: rpthjournal.org/article/S2475-…

Thrilled to announce our publication in AJHP! This review demonstrates an area of improvement where we can focus our efforts to stopping inappropriate triple antithrombotic therapy to minimize bleeding #anticoagulationstewardship #thrombosisandhemostasis doi.org/10.1093/ajhp/z…